Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

75.79
-0.8100-1.06%
Volume:651.90K
Turnover:49.32M
Market Cap:14.84B
PE:-21.24
High:76.77
Open:76.20
Low:75.03
Close:76.60
52wk High:93.42
52wk Low:48.78
Shares:195.81M
Float Shares:167.00M
Volume Ratio:0.74
T/O Rate:0.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.90
PE(LYR):-20.02

Loading ...

U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation

Reuters
·
Jun 16

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and BridgeBio Pharma (BBIO)

TIPRANKS
·
Jun 16

BRIEF-DKSH Enters Strategic Distribution Partnership With Bridgebio

Reuters
·
Jun 11

DKSH partners with BridgeBio to distribute ATTR-CM transthyretin stabilizer in Asia-Pacific markets

Reuters
·
Jun 11

BridgeBio CEO Neil Kumar reports $4.26 million common share disposal

Reuters
·
Jun 09

Barclays Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
Jun 05

How FDA Priority Review for First-in-Class LGMD Drug BBP-418 Could Impact BridgeBio Pharma (BBIO) Investors

Simply Wall St.
·
Jun 05

BridgeBio Pharma Inc : Canaccord Genuity Initiates Coverage With Buy Rating; Price Target $104

THOMSON REUTERS
·
Jun 03

Canaccord Genuity Initiates BridgeBio Pharma at Buy With $104 Price Target

MT Newswires Live
·
Jun 03

BridgeBio initiated with a Buy at Canaccord

TIPRANKS
·
Jun 03

BridgeBio publishes corporate presentation outlining rare-disease pipeline and 2026 milestones

Reuters
·
Jun 03

BridgeBio price target raised to $98 from $94 at Morgan Stanley

TIPRANKS
·
May 28

BridgeBio Pharma Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 28

BridgeBio Pharma Price Target Maintained With a $110.00/Share by HC Wainwright & Co.

Dow Jones
·
May 28

Analysts Are Bullish on These Healthcare Stocks: Bristol-Myers Squibb (BMY), BridgeBio Pharma (BBIO)

TIPRANKS
·
May 28

BridgeBio announces FDA acceptance, priority review of BBP-418 NDA

TIPRANKS
·
May 27

BridgeBio Pharma Says FDA Accepts Muscular Dystrophy Drug Application for Priority Review

MT Newswires Live
·
May 27

BridgeBio says FDA accepts BBP-418 NDA for LGMD2I/R9, grants priority review

Reuters
·
May 27

BridgeBio Announces FDA Acceptance and Priority Review of Nda for Bbp-418 for Lgmd2i/R9

THOMSON REUTERS
·
May 27

BridgeBio Pharma Inc - FDA Sets Pdufa Target Action Date of November 27, 2026 for Bbp-418

THOMSON REUTERS
·
May 27